Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Acquisitions & Divestments (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with $35.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 30.41% to $35.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $169.9 million, a 7.6% increase, with the full-year FY2024 number at $176.8 million, down 37.73% from a year prior.
  • Change in Acquisitions & Divestments was $35.9 million for Q3 2025 at Century Therapeutics, down from $42.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $110.5 million in Q2 2023 to a low of $29.3 million in Q4 2023.
  • A 4-year average of $56.9 million and a median of $51.6 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 93.17% in 2023, then tumbled 72.97% in 2024.
  • Century Therapeutics' Change in Acquisitions & Divestments stood at $52.3 million in 2022, then crashed by 44.06% to $29.3 million in 2023, then skyrocketed by 64.59% to $48.2 million in 2024, then fell by 25.52% to $35.9 million in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Change in Acquisitions & Divestments are $35.9 million (Q3 2025), $42.5 million (Q2 2025), and $43.3 million (Q1 2025).